VERWENDUNG VON HUMANEN OATP-C POLYMORPHISMEN, DIE EINEN EFFEKT AUF DIE PHARMAKOKINETIK VON STATIN HABEN, BEI DER STATIN-THERAPIE

摘要

This invention relates to use of polymorphisms in human OATP-C in statin therapy because they are associated with an effect on statin pharmacokinetics (PK) in humans, especially rosuvastatin pharmacokinetics. The invention also relates to the use of OATP-C polymorphisms in predicting the efficacy and safety of statins, whose uptake in to the liver is mediated by OATP-C, especially rosuvastatin.